iOrganBio, an innovator in intelligent cell manufacturing that is redefining how human cells are engineered and reliably produced at scale for research and therapeutic applications, today announced the appointment of Jessica Owens to its Board of Directors. Owens is a seasoned venture investor and serial founder with extensive experience building and scaling companies at the intersection of life sciences, health technology and AI.
Owens brings over 20 years of company-building and investing experience, including co-founding GRAIL, which raised over $1 billion and formed partnerships with Bristol Myers Squibb, Merck, and Johnson & Johnson, and serving as co-founder and General Partner at Initiate Ventures. Her appointment comes as iOrganBio scales its CellForge platform, expands partnerships, and advances AI-driven cell manufacturing to improve predictability and scalability from model development to cell therapies.
“We are thrilled to welcome Jessica to the iOrganBio Board of Directors,” said a spokesperson for the company. “Her deep expertise in building and investing in life sciences and AI companies will be invaluable as we accelerate the commercialization of CellForge and expand our impact on drug development and regenerative medicine.”
iOrganBio is transforming human cell production with CellForge, its AI-powered platform for consistent, scalable, and intelligent manufacturing of cells and organoids for in vitro modeling and cell therapies. By applying engineering precision to biology, CellForge uses AI and automation to guide cell development and make real-time adjustments aligned with defined biological profiles. At the core of the platform is iOrganBio’s functional human CellAtlas, a comprehensive reference built from single-cell and multi-omics data that provides the digital blueprints for each cell type. This smart, closed-loop process delivers the accuracy, efficiency, and quality partners need to turn scientific ideas into breakthroughs, accelerating disease modeling, regenerative medicine, and drug development.
The appointment of Owens signals iOrganBio’s commitment to leveraging AI and advanced manufacturing to address critical challenges in cell therapy and drug development. With her background, Owens is expected to help guide the company’s strategy as it scales operations and pursues partnerships with pharmaceutical and biotechnology companies. The move also highlights the growing importance of AI-driven solutions in the life sciences sector, where precision and scalability are key to commercial success.
iOrganBio is based at BioLabs in Chapel Hill, NC. For more information, visit iOrgan.Bio.
